This inventor holds 16 USPTO granted patents. Top assignees: Lynx Therapeutics, Inc., Geron Corporation. Active years: 1997-2019.
Location History:
- Hayward, CA (US) (1998)
- Fremont, CA (US) (1997 - 1999)
- Urbana, MO (US) (1999 - 2019)
Company Filing History:
Years Active: 1997-2019
Title: The Innovative Contributions of Ronald G Schultz
Introduction
Ronald G Schultz is a prominent inventor based in Urbana, MO (US), known for his significant contributions to the field of oligonucleotide chemistry. With a total of 16 patents to his name, Schultz has made remarkable advancements that have implications in various scientific and medical applications.
Latest Patents
Among his latest patents are the 2'-arabino-fluorooligonucleotide N3′→P5′ phosphoramidates. These innovative oligonucleotides feature a novel sugar-phosphate backbone that includes at least one 2'-arabino-fluoronucleoside. The internucleoside 3′-NH—P(—O)(OR)—O-5′ linkage, where R can be a positively charged counter ion or hydrogen, enhances their functionality. The inventive phosphoramidate 2'-arabino-fluorooligonucleotides exhibit a high RNA binding affinity to complementary nucleic acids and demonstrate stability in both acidic and basic conditions.
Career Highlights
Throughout his career, Ronald G Schultz has worked with notable companies such as Lynx Therapeutics, Inc. and Geron Corporation. His work in these organizations has contributed to the development of cutting-edge technologies in the field of biotechnology and pharmaceuticals.
Collaborations
Schultz has collaborated with esteemed colleagues, including Sergei M Gryaznov and Jer-Kang Chen. These partnerships have further enriched his research and innovation efforts.
Conclusion
Ronald G Schultz's contributions to oligonucleotide chemistry and his extensive patent portfolio underscore his role as a leading inventor in the field. His work continues to influence advancements in biotechnology and medicine.